MikroScore
New papers, curated and contextualized

New Research This Week (2026-07-18)

Quercetin in a first RCT for altitude sickness, vitamin D3 in endometriosis and pregnancy, omega-3 in periodontitis, astaxanthin in female endurance athletes, and iron dosing in pregnancy.

Published: 18/07/2026 quercetinvitamin-d3omega-3astaxanthineisenresearch-review

New Research This Week (2026-07-18)

Key Takeaways

For this edition, I selected the five strongest signals from current research with a focus on evidence quality.

The standout this week is methodological: quercetin appears for the first time in a double-blind RCT for an entirely different indication than its usual inflammatory-marker territory. Alongside it: two new vitamin D3 RCTs in gynecological populations, an omega-3 meta-analysis from dentistry, a tight astaxanthin crossover RCT, and a clinically practical iron dosing study from pregnancy.

This Week’s 5 Strongest Signals

1) Quercetin

The most surprising signal this week: European Journal of Nutrition published a double-blind, placebo-controlled, phase II RCT on quercetin for the prophylaxis of acute mountain sickness (AMS). This is an indication that has effectively not existed in the quercetin literature before — which automatically makes it more interesting than another CRP-reduction trial.

The setup is clear: AMS is a well-defined problem triggered by rapid ascent to altitude (typically > 2,500 m), driven by hypoxia and inflammatory responses. The quercetin mechanism is plausible here: antioxidant and anti-inflammatory action under hypoxia-induced oxidative stress. What makes this RCT notable is not only the clinically tangible endpoint (Lake Louise Score, headache, nausea) but the methodological rigor: double-blind, placebo-controlled, with pre-ascent supplementation.

For MikroScore, this is editorially meaningful because it pulls quercetin out of vague anti-aging territory and into a concrete, testable application context. The open question: how robust are the effect sizes, and what dose was used?

Relevant Paper

  • Quercetin prophylaxis in prevention of acute mountain sickness (AMS): a randomized, double blind, placebo controlled phase-II clinical trial
    Journal: European Journal of Nutrition
    Link: https://pubmed.ncbi.nlm.nih.gov/42435069/

MikroScore Assessment

If the effect size and dosing hold up in the full text, this is a genuine update candidate for the quercetin dossier — specifically for a section on clinical niche applications. Quercetin for AMS prophylaxis is mechanistically coherent and better supported than most quercetin lifestyle claims.

→ Ingredient profile: /en/ingredients/quercetin

2) Vitamin D3

Two new vitamin D3 RCTs appeared this week in gynecological and obstetric contexts — an area where D3 already has solid evidence, but where new studies sharpen the differentiation.

The first RCT (Scientific Reports, 2026) investigated adjunctive vitamin D3 in women receiving dienogest therapy for endometriosis. The design is methodologically sound: double-blind, placebo-controlled, n=66 women with vitamin D below 30 ng/mL, 8 weeks, 4,000 IU every other day. The primary result is, however, negative: habitual pain (ENDOPAIN-4D) was numerically lower in the D3 group (38.8 vs. 50.1) but did not reach statistical significance (AMD: −11.3; 95% CI: −26.2 to +3.5; p=0.136). The study was likely underpowered (n=66), and the dominant dienogest effect may have masked any D3 add-on benefit. Bottom line: an interesting question, but no convincing evidence of clinical efficacy.

The second RCT (Journal of Clinical Endocrinology & Metabolism) is the preg-D trial: D3 supplementation in hypovitaminosis D pregnancy, with maternal and neonatal outcomes as endpoints. The journal matters — JCEM is not a supplement-friendly niche publication but one of the most influential endocrinology journals, and publication there gives the data considerably more weight.

Relevant Papers

  • Adjunctive vitamin D supplementation in women receiving dienogest therapy for endometriosis: a randomized controlled trial
    Journal: Scientific Reports
    Link: https://pubmed.ncbi.nlm.nih.gov/42463771/

  • Maternal and neonatal outcomes of vitamin D supplementation in hypovitaminosis D pregnancy: preg-D randomized trial
    Journal: Journal of Clinical Endocrinology & Metabolism
    Link: https://pubmed.ncbi.nlm.nih.gov/42461330/

MikroScore Assessment

Vitamin D3 is accumulating further clinical data points for specific risk groups. For the dossier, the gynecological contexts (pregnancy, endometriosis) are the most relevant additions — not as support for general supplementation recommendations, but as precision on where D3 becomes most clinically meaningful.

→ Ingredient profile: /en/ingredients/vitamin-d3

3) Omega-3

BMC Oral Health published a systematic review and meta-analysis examining omega-3 fatty acids as an adjunct to non-surgical periodontal therapy (scaling and root planing). This is a niche indication — but a methodologically interesting one, because periodontitis is a chronic inflammatory context where omega-3 mechanisms (lipoxins, resolvins) are biologically directly applicable.

Meta-analyses on omega-3 in dentistry are rare, and combining it with an established standard therapy (SRP) makes the question clinically relevant: does omega-3 measurably improve the treatment response? If so, in which endpoints — clinical attachment level, pocket depth, inflammatory markers?

Relevant Paper

  • Evaluation of the effect of omega-3 fatty acids supplementation as an adjunct to non-surgical periodontal therapy: a systematic review and meta-analysis
    Journal: BMC Oral Health
    Link: https://pubmed.ncbi.nlm.nih.gov/42458370/

MikroScore Assessment

For the omega-3 dossier, this is most relevant as an example of a less well-known but clinically grounded niche application — not as a core argument for general omega-3 supplementation. The mechanism via resolvins and protectins is real; whether the clinical effects justify routine adjunct use in periodontal practice depends on effect size and cost context.

→ Ingredient profile: /en/ingredients/omega-3

4) Astaxanthin

Journal of Dietary Supplements published a randomized, double-blind, placebo-controlled crossover RCT on astaxanthin supplementation and respiratory exchange ratio (RER) during submaximal cycling in women. Methodologically this is solid: crossover design, double-blind, clear biomarker endpoint.

The RER measures the ratio of CO₂ produced to O₂ consumed and is a proxy for substrate utilization during exercise — a lower RER suggests greater fat oxidation. This is mechanistically plausible for astaxanthin, known as a potent antioxidant that has shown effects on mitochondrial function and lipid metabolism in preclinical models.

The female-specific design is noteworthy for MikroScore: many exercise studies are male-dominated, and sex-specific effects in antioxidant supplementation are real but rarely specifically studied.

Relevant Paper

  • Astaxanthin Supplementation Lowers Respiratory Exchange Ratio During Submaximal Cycling in Females: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
    Journal: Journal of Dietary Supplements
    Link: https://pubmed.ncbi.nlm.nih.gov/42467594/

MikroScore Assessment

This is not a cardiovascular endpoint trial — but it is a clean biomarker RCT with a female-specific focus. For the astaxanthin dossier in the sport and endurance context, this is a relevant, methodologically convincing single signal. Not a basis for broad conclusions, but a legitimate update candidate for the endurance section.

→ Ingredient profile: /en/ingredients/astaxanthin

5) Iron

Blood Advances published data from the PANDA trial on the impact of different oral iron dosing regimens on iron biomarkers during pregnancy. This is not a spectacular new discovery, but it is clinically practical: how often and at what dose to supplement iron in pregnancy is a direct question for obstetricians and expecting mothers.

What makes PANDA stand out: Blood Advances is a high-quality hematology journal, and dosing-regimen studies are rarely published at this quality level. Daily vs. alternate-day vs. weekly dosing — this has direct implications for side-effect profile (nausea, constipation) and compliance throughout pregnancy.

Relevant Paper

MikroScore Assessment

For the iron dossier, this is most relevant for the section on pregnancy and dosing logic. The practical question of “when and how often?” has far more everyday relevance for users than purely mechanistic data. Update candidate for the dosing and usage section.

→ Ingredient profile: /en/ingredients/eisen

What I Deliberately Left Out

  • ClinicalTrials.gov registrations without results (NR in kidney disease, taurine in post-COVID, magnesium for sleep in women)
  • Irrelevant keyword hits (tyrosine kinase inhibitors ≠ L-tyrosine; copper PET tracers ≠ copper supplement; creatine kinase ≠ creatine)
  • Preprints without peer review
  • Papers with only loose or absent supplement relevance

Transparency Note

This page is an editorial weekly overview of new research signals. It does not replace a full ingredient evaluation and does not make EU-compliant health claims on its own.